An Open Label, Single-dose, Multi-center, Parallel-group, Two-staged Study to Evaluate Pharmacokinetics of Oral cMET Inhibitor INC280 in Non-Cancer Subjects With Impaired Hepatic Function and Non-Cancer Subjects With Normal Hepatic Function

Trial Profile

An Open Label, Single-dose, Multi-center, Parallel-group, Two-staged Study to Evaluate Pharmacokinetics of Oral cMET Inhibitor INC280 in Non-Cancer Subjects With Impaired Hepatic Function and Non-Cancer Subjects With Normal Hepatic Function

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Capmatinib (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 1 Sep 2017 to 30 Aug 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Aug 2017.
    • 14 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top